Beneficial effects of SR33805 in failing myocardium

Younss Ait Mou, Attila Toth, Cécile Cassan, Daniel Czuriga, Pieter P. De Tombe, Zoltan Papp, Alain Lacampagne, Olivier Cazorla

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Aims SR33805, a potent Ca 2+ channel blocker, increases cardiac myofilament Ca 2+ sensitivity in healthy rat cardiomyocytes. Therefore, the aim of the present study was to evaluate the effects of SR33805 on contractile properties in ischaemic failing hearts after myocardial infarction (MI) in vivo and in vitro at the cellular level. Methods and results The effect of SR33805 (10 M) was tested on the excitationcontraction coupling of cardiomyocytes isolated from rat with end-stage heart failure. Cell shortening and Ca 2+ transients were measured in intact cardiomyocytes, while contractile properties were determined in Triton X-100 permeabilized myocytes. Acute treatment with SR33805 restored the MI-altered cell shortening without affecting the Ca 2+ transient amplitude, suggesting an increase of myofilament Ca 2+ sensitivity in MI myocytes. Indeed, a SR33805-induced sensitization of myofilament activation was found to be associated with a slight increase in myosin light chain-2 phosphorylation and a more significant decrease on troponin I (TnI) phosphorylation. Decreased TnI phosphorylation was related to inhibition of protein kinase A activity by SR33805. Finally, administration of a single intra-peritoneal bolus of SR33805 (20 mg/kg) improved end-systolic strain and fractional shortening of MI hearts. Conclusion The present study indicates that treatment with SR33805 improved contractility of ischaemic failing hearts after MI in the rat by selectively modulating the phosphorylation status of sarcomeric regulatory proteins, which then sensitized the myofilaments to Ca 2+. Our results gave a proof of concept that manipulation of the Ca 2+ sensitivity of sarcomeric regulatory proteins can be used to improve contractility of a failing heart.

Original languageEnglish
Pages (from-to)412-419
Number of pages8
JournalCardiovascular Research
Volume91
Issue number3
DOIs
Publication statusPublished - 1 Aug 2011
Externally publishedYes

Fingerprint

Myofibrils
Myocardium
Myocardial Infarction
Phosphorylation
Cardiac Myocytes
Troponin I
Muscle Cells
Octoxynol
Cyclic AMP-Dependent Protein Kinases
Proteins
Heart Failure

Keywords

  • Contractile function
  • Heart failure
  • Myocytes
  • Sarcomere
  • Ventricular function

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Physiology

Cite this

Ait Mou, Y., Toth, A., Cassan, C., Czuriga, D., De Tombe, P. P., Papp, Z., ... Cazorla, O. (2011). Beneficial effects of SR33805 in failing myocardium. Cardiovascular Research, 91(3), 412-419. https://doi.org/10.1093/cvr/cvr096

Beneficial effects of SR33805 in failing myocardium. / Ait Mou, Younss; Toth, Attila; Cassan, Cécile; Czuriga, Daniel; De Tombe, Pieter P.; Papp, Zoltan; Lacampagne, Alain; Cazorla, Olivier.

In: Cardiovascular Research, Vol. 91, No. 3, 01.08.2011, p. 412-419.

Research output: Contribution to journalArticle

Ait Mou, Y, Toth, A, Cassan, C, Czuriga, D, De Tombe, PP, Papp, Z, Lacampagne, A & Cazorla, O 2011, 'Beneficial effects of SR33805 in failing myocardium', Cardiovascular Research, vol. 91, no. 3, pp. 412-419. https://doi.org/10.1093/cvr/cvr096
Ait Mou Y, Toth A, Cassan C, Czuriga D, De Tombe PP, Papp Z et al. Beneficial effects of SR33805 in failing myocardium. Cardiovascular Research. 2011 Aug 1;91(3):412-419. https://doi.org/10.1093/cvr/cvr096
Ait Mou, Younss ; Toth, Attila ; Cassan, Cécile ; Czuriga, Daniel ; De Tombe, Pieter P. ; Papp, Zoltan ; Lacampagne, Alain ; Cazorla, Olivier. / Beneficial effects of SR33805 in failing myocardium. In: Cardiovascular Research. 2011 ; Vol. 91, No. 3. pp. 412-419.
@article{7211ec0664fb4d6890999940c6baa825,
title = "Beneficial effects of SR33805 in failing myocardium",
abstract = "Aims SR33805, a potent Ca 2+ channel blocker, increases cardiac myofilament Ca 2+ sensitivity in healthy rat cardiomyocytes. Therefore, the aim of the present study was to evaluate the effects of SR33805 on contractile properties in ischaemic failing hearts after myocardial infarction (MI) in vivo and in vitro at the cellular level. Methods and results The effect of SR33805 (10 M) was tested on the excitationcontraction coupling of cardiomyocytes isolated from rat with end-stage heart failure. Cell shortening and Ca 2+ transients were measured in intact cardiomyocytes, while contractile properties were determined in Triton X-100 permeabilized myocytes. Acute treatment with SR33805 restored the MI-altered cell shortening without affecting the Ca 2+ transient amplitude, suggesting an increase of myofilament Ca 2+ sensitivity in MI myocytes. Indeed, a SR33805-induced sensitization of myofilament activation was found to be associated with a slight increase in myosin light chain-2 phosphorylation and a more significant decrease on troponin I (TnI) phosphorylation. Decreased TnI phosphorylation was related to inhibition of protein kinase A activity by SR33805. Finally, administration of a single intra-peritoneal bolus of SR33805 (20 mg/kg) improved end-systolic strain and fractional shortening of MI hearts. Conclusion The present study indicates that treatment with SR33805 improved contractility of ischaemic failing hearts after MI in the rat by selectively modulating the phosphorylation status of sarcomeric regulatory proteins, which then sensitized the myofilaments to Ca 2+. Our results gave a proof of concept that manipulation of the Ca 2+ sensitivity of sarcomeric regulatory proteins can be used to improve contractility of a failing heart.",
keywords = "Contractile function, Heart failure, Myocytes, Sarcomere, Ventricular function",
author = "{Ait Mou}, Younss and Attila Toth and C{\'e}cile Cassan and Daniel Czuriga and {De Tombe}, {Pieter P.} and Zoltan Papp and Alain Lacampagne and Olivier Cazorla",
year = "2011",
month = "8",
day = "1",
doi = "10.1093/cvr/cvr096",
language = "English",
volume = "91",
pages = "412--419",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Beneficial effects of SR33805 in failing myocardium

AU - Ait Mou, Younss

AU - Toth, Attila

AU - Cassan, Cécile

AU - Czuriga, Daniel

AU - De Tombe, Pieter P.

AU - Papp, Zoltan

AU - Lacampagne, Alain

AU - Cazorla, Olivier

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Aims SR33805, a potent Ca 2+ channel blocker, increases cardiac myofilament Ca 2+ sensitivity in healthy rat cardiomyocytes. Therefore, the aim of the present study was to evaluate the effects of SR33805 on contractile properties in ischaemic failing hearts after myocardial infarction (MI) in vivo and in vitro at the cellular level. Methods and results The effect of SR33805 (10 M) was tested on the excitationcontraction coupling of cardiomyocytes isolated from rat with end-stage heart failure. Cell shortening and Ca 2+ transients were measured in intact cardiomyocytes, while contractile properties were determined in Triton X-100 permeabilized myocytes. Acute treatment with SR33805 restored the MI-altered cell shortening without affecting the Ca 2+ transient amplitude, suggesting an increase of myofilament Ca 2+ sensitivity in MI myocytes. Indeed, a SR33805-induced sensitization of myofilament activation was found to be associated with a slight increase in myosin light chain-2 phosphorylation and a more significant decrease on troponin I (TnI) phosphorylation. Decreased TnI phosphorylation was related to inhibition of protein kinase A activity by SR33805. Finally, administration of a single intra-peritoneal bolus of SR33805 (20 mg/kg) improved end-systolic strain and fractional shortening of MI hearts. Conclusion The present study indicates that treatment with SR33805 improved contractility of ischaemic failing hearts after MI in the rat by selectively modulating the phosphorylation status of sarcomeric regulatory proteins, which then sensitized the myofilaments to Ca 2+. Our results gave a proof of concept that manipulation of the Ca 2+ sensitivity of sarcomeric regulatory proteins can be used to improve contractility of a failing heart.

AB - Aims SR33805, a potent Ca 2+ channel blocker, increases cardiac myofilament Ca 2+ sensitivity in healthy rat cardiomyocytes. Therefore, the aim of the present study was to evaluate the effects of SR33805 on contractile properties in ischaemic failing hearts after myocardial infarction (MI) in vivo and in vitro at the cellular level. Methods and results The effect of SR33805 (10 M) was tested on the excitationcontraction coupling of cardiomyocytes isolated from rat with end-stage heart failure. Cell shortening and Ca 2+ transients were measured in intact cardiomyocytes, while contractile properties were determined in Triton X-100 permeabilized myocytes. Acute treatment with SR33805 restored the MI-altered cell shortening without affecting the Ca 2+ transient amplitude, suggesting an increase of myofilament Ca 2+ sensitivity in MI myocytes. Indeed, a SR33805-induced sensitization of myofilament activation was found to be associated with a slight increase in myosin light chain-2 phosphorylation and a more significant decrease on troponin I (TnI) phosphorylation. Decreased TnI phosphorylation was related to inhibition of protein kinase A activity by SR33805. Finally, administration of a single intra-peritoneal bolus of SR33805 (20 mg/kg) improved end-systolic strain and fractional shortening of MI hearts. Conclusion The present study indicates that treatment with SR33805 improved contractility of ischaemic failing hearts after MI in the rat by selectively modulating the phosphorylation status of sarcomeric regulatory proteins, which then sensitized the myofilaments to Ca 2+. Our results gave a proof of concept that manipulation of the Ca 2+ sensitivity of sarcomeric regulatory proteins can be used to improve contractility of a failing heart.

KW - Contractile function

KW - Heart failure

KW - Myocytes

KW - Sarcomere

KW - Ventricular function

UR - http://www.scopus.com/inward/record.url?scp=79960819821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960819821&partnerID=8YFLogxK

U2 - 10.1093/cvr/cvr096

DO - 10.1093/cvr/cvr096

M3 - Article

VL - 91

SP - 412

EP - 419

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 3

ER -